Brief: Hillevax Announces Results From 5-Year Clinical Study
20/07/2022 22:00
July 20 (Reuters) - Hillevax Inc HLVX.O :
* HILLEVAX ANNOUNCES RESULTS FROM 5-YEAR CLINICAL STUDY
SUPPORTING
LONG-TERM IMMUNOGENICITY OF HIL-214 NOROVIRUS VACCINE CANDIDATE
* HILLEVAX INC - NO ADVERSE EVENTS DEEMED RELATED TO HIL-214
* HILLEVAX INC - ANTICIPATES PRESENTING DETAILED DATA FROM
NOR-213
CLINICAL TRIAL AT A FUTURE MEDICAL MEETING
Source text for Eikon: ID:nGNX93bJwC
Further company coverage: HLVX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HilleVax
See all newsBrief: XOMA Royalty Announces Closing Of Tender Offer For HilleVax
Brief: Hillevax Enters Into A Definitive Agreement To Be Acquired By Xoma Royalty For $1.95 In Cash Per Share Plus A Contingent Value Right
U.S. STOCKS ON THE MOVE-US energy sector, Oshkosh, Meta
U.S. STOCKS ON THE MOVE-Zumiez, BTC Digital, WesBanco
U.S. STOCKS ON THE MOVE-Petco Health, Smith & Wesson, Victoria's Secret